Nxera Pharma Co., Ltd. SOLTF
10.50 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
10.50 Day range 10.50
4.90 52-week range 10.93
- YTD
- +91.61%
- 1 year
- +90.91%
News
seekingalpha.com Nxera Pharma Co., Ltd. (SOLTF) Q3 2026 Earnings Call Transcript Nxera Pharma Co., Ltd. (SOLTF) Q3 2026 Earnings Call Transcript
seekingalpha.com Nxera Pharma Co., Ltd. (SOLTF) Q2 2026 Earnings Call Transcript Nxera Pharma Co., Ltd. (SOLTF) Q2 2026 Earnings Call Transcript
globenewswire.com Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the…
globenewswire.com Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea Tokyo, Japan and Cambridge, UK, 2 June 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan…
globenewswire.com Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026 Tokyo, Japan and Cambridge, UK, 26 May 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat' at the…
globenewswire.com Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established company…
globenewswire.com Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”)…
globenewswire.com Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases Tokyo, Japan and Cambridge and London, UK, 20 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&D milestone under its multi-target…
defenseworld.net Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF) Short Interest Update Nxera Pharma Co., Ltd. (OTCMKTS:SOLTF - Get Free Report) saw a significant decline in short interest in March. As of March 31st, there was short interest totaling 1,523,938 shares, a decline of 13.8%…
globenewswire.com Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia Tokyo, Japan and Cambridge, UK, 14 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Holling Bio-Pharma Corp. (“Holling”), a leading pharmaceutical…
globenewswire.com Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia Tokyo, Japan and Cambridge, UK, 13 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated…
globenewswire.com Nxera Pharma Achieves Second Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases Tokyo, Japan and Cambridge, UK, 09 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a second development milestone under its multi-target…
globenewswire.com Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa's OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and…
globenewswire.com Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development…
globenewswire.com Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the Ministry…
seekingalpha.com Nxera Pharma Co., Ltd. (SOLTF) Q4 2025 Earnings Call Transcript Nxera Pharma Co., Ltd. (SOLTF) Q4 2025 Earnings Call Transcript
globenewswire.com Nxera Pharma Proposes Changes to its Board of Directors Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated…
globenewswire.com Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025 Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for…
globenewswire.com Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone…
globenewswire.com Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has entered into a license agreement (the “Agreement”) with a newly…